Clinical trials: Glioma Surgery
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Feasibility of ONCOhabitats for Surgical and Treatment Planning in IDH-Wildtype Glioblastoma (SINUE)
The goal of this clinical trial is to validate ONCOhabitats, an advanced imaging software, as a medical device for the clinical management of IDH-wildtype glioblastoma.
- Trial name
- SINUE (NCT07111195)
- Testing
- The ONCOhabitats software for MRI-based habitat segmentation
- Where
- 5 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Juan M Garcia-Gomez
Adult Giant Cell Glioblastoma, Adult Glioblastoma
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
This randomized phase II trial is studying how well GDC-0449 works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00980343
- Testing
- vismodegib, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- 9 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme
This randomized phase II trial is studying how well neoadjuvant and adjuvant fenretinide works compared to adjuvant fenretinide alone in treating patients who are undergoing surgical resection for recurrent glioblastoma…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00075491
- Testing
- fenretinide, therapeutic conventional surgery, pharmacological study
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma
This clinical trial is using EF5 to measure the oxygen level in tumor cells of patients undergoing surgery or surgery biopsy for newly diagnosed supratentorial malignant glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma
- Trial name
- NCT00430079
- Testing
- etanidazole, conventional surgery, pharmacological study
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma (GBM)
Limited Target Volume Radiotherapy After Glioblastoma Surgery
Research on radiotherapy target volumes for glioblastoma is increasingly focused on exploring more limited yet effective irradiation fields, aiming to achieve local control while minimizing acute and long-term neurotoxicity.
- Trial name
- NCT07368283
- Testing
- limited-field radiotherapy
- Volunteers
- 79 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Brain Tumor, Recurrent, Vestibular Schwannoma
Vegetative Monitoring During Brainstem-associated Surgery
Intraoperative Monitoring of Heart rate variability, Blood pressure variability, Baroreceptorsensivity etc.
- Conditions
- Brain Tumor, Recurrent, Vestibular Schwannoma, Brainstem Neoplasm, Brainstem Glioma
- Trial name
- NCT03666507
- Testing
- Intraoperative Monitoring during resection of brain tumor
- Where
- Germany
- Volunteers
- 103 people
- Sponsor
- University Hospital Tuebingen
Glioma, Glioblastoma Multiforme
Genetic Analysis of Brain Tumors
This study will analyze tissue and blood samples from patients with gliomas (a type of brain tumor) to develop a new classification system for these tumors.
- Conditions
- Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT00031538
- Where
- 3 sites in United States
- Volunteers
- 674 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Anaplastic Oligoastrocytoma
Study About the Validity of MRS-guided Resection on Prognosis High-grade Glioma Gliomas
Gliomas,especially high-grade glioma ,are the most common primary malignant brain tumor in adults,yet outcomes from this aggressive neoplasm remain dismal.The extent of resection is one of the most essential factors that…
- Conditions
- Glioma, Anaplastic Oligoastrocytoma, Glioblastomas (GBM)
- Trial name
- NCT02795364
- Testing
- Structural Image Guidance, Metabolic Image Guidance
- Volunteers
- 50 people
- Sponsor
- Huashan Hospital
Glioblastoma, Glioblastoma Multiforme
The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.
The trial is designed as a multicenter randomized controlled study. 246 patients with presumed Glioblastoma Multiforme in eloquent areas on diagnostic MRI will be selected by the neurosurgeons according the eligibility criteria…
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Astrocytoma, Grade IV
- Trial name
- SAFE (NCT03861299)
- Testing
- Awake craniotomy, Craniotomy under general anesthesia
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 246 people
- Sponsor
- Jasper Gerritsen
Low-grade Glioma, IDH2 Gene Mutation
Niraparib In Recurrent IDH 1/2 Gliomas
This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2 mutant glioma.
- Conditions
- Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma, IDH1 Mutation
- Trial name
- NCT05406700
- Testing
- Niraparib, Resection/Treatment with Niraparib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Glioblastoma
PH Sensitive MRI Based Resections of Glioblastoma
Current standard of care therapy and all FDA approved adjuvant therapy for glioblastoma continue to provide less than 12 months of progression free survival (PFS) and less than 24 months of overall survival (OS).
- Trial name
- NCT06176066
- Testing
- CEST PH MRI based resection of glioblastoma
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, Los Angeles
Brain Neoplasm, Malignant Glioma
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
This study is a phase 1-2 trial that evaluates the best dose of cetuximab-IRDye 800CW and how well it works in detecting tumors in patients with malignant glioma who are undergoing surgery.
- Trial name
- NCT02855086
- Testing
- Cetuximab, Cetuximab-IRDye 800CW, Tumor resection
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Eben Rosenthal
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
- Trial name
- NCT00003461
- Testing
- surgical procedure, astatine At 211 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Glioma
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma
This is an open-label brain PET/CT (positron emission tomography/computed tomography) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-BNOTA-PRGD2 in glioma patients.
- Trial name
- GRGDG (NCT01801371)
- Testing
- 68Ga-BNOTA-PRGD2
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Brain Neoplasms
Improving Surgical Outcomes in Patients With Low Grade Gliomas Using Advanced Pre- and Intra-operative MRI
This aim of this study is to improve the outcomes for patient with gliomas undergoing neurosurgery by maximising the extent of resection whilst minimising neurological morbidity.
- Trial name
- NCT02884947
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- University College, London
Astrocytoma, Glioblastoma
Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor
Glioblastomas, the most frequent malignant brain tumor in adults, are widespread in the brain, despite their discrete appearance on computed tomography (CT) or magnetic resonance imaging (MRI).
- Conditions
- Astrocytoma, Glioblastoma, Glioma
- Trial name
- NCT00001148
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Brain Tumor, Glioma
Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas
5-ALA and the Orbeye surgical microscope are U.S. Food and Drug Administration (FDA) approved products. For this study, the Orbeye microscope imaging system is being used with special filters to visualize 5-ALA fluorescence.
- Trial name
- NCT04055688
- Testing
- Orbeye surgical videomicroscope, 5-Aminolevulinic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Recurrent Glioma, Glioma, Malignant
Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
role of surgery in treatment of recurrent brain glioma prognostic factors and outcome measures Role of surgery : In patients with Grade I gliomas, such as pilocytic astrocytomas, resection is potentially curative.
- Trial name
- NCT04562077
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Assiut University
Glioblastoma, Adult
Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)
Fluorescence guidance is a safe and efficient tool for glioblastomas resection. The most widely used technique is based on 5-aminolevulinic acid (5ala), which stains glioblastoma cells through a metabolic abnormality and thus…
- Trial name
- FLEGME (NCT03291977)
- Testing
- Fluorescéine Sodique Faure, White-light surgery
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Rennes University Hospital
Recurrent Glioblastoma
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in…
- Trial name
- NCT07209241
- Testing
- CART-EGFR-IL13Ra2 T cells
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Pennsylvania